Cited by 77Cancer, Lipids, and MetabolismPI3K/AKT/mTOR signaling in cancerSphingolipid Metabolism and Signaling

Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways

Open access
Kim, Seong M., Roy, Saurabh G., Chen, Bin, Nguyen, Tiffany M., McMonigle, Ryan J., McCracken, Alison N., Zhang, Yanling, Kofuji, Satoshi +16 more·2016·Journal of Clinical Investigation

Abstract

Oncogenic mutations drive anabolic metabolism, creating a dependency on nutrient influx through transporters, receptors, and macropinocytosis. While sphingolipids suppress tumor growth by downregulating nutrient transporters, macropinocytosis and autophagy still provide cancer cells with fuel. Therapeutics that simultaneously disrupt these parallel nutrient access pathways have potential as powerful starvation agents. Here, we describe a water-soluble, orally bioavailable synthetic sphingolipid, SH-BC-893, that triggers nutrient transporter internalization and also blocks lysosome-dependent nutrient generation pathways. SH-BC-893 activated protein phosphatase 2A (PP2A), leading to mislocalization of the lipid kinase PIKfyve. The concomitant mislocalization of the PIKfyve product PI(3,5)P2 triggered cytosolic vacuolation and blocked lysosomal fusion reactions essential for LDL, autophagosome, and macropinosome degradation. By simultaneously limiting access to both extracellular and intracellular nutrients, SH-BC-893 selectively killed cells expressing an activated form of the anabolic oncogene Ras in vitro and in vivo. However, slower-growing, autochthonous PTEN-deficient prostate tumors that did not exhibit a classic Warburg phenotype were equally sensitive. Remarkably, normal proliferative tissues were unaffected by doses of SH-BC-893 that profoundly inhibited tumor growth. These studies demonstrate that simultaneously blocking parallel nutrient access pathways with sphingolipid-based drugs is broadly effective and cancer selective, suggesting a potential strategy for overcoming the resistance conferred by tumor heterogeneity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci87148

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 62 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kim, S. M., Roy, S. G., Chen, B., Nguyen, T. M., McMonigle, R. J., McCracken, A. N., Zhang, Y., Kofuji, S., Hou, J., Selwan, E., Finicle, B. T., Nguyen, T. T., Ravi, A., Ramirez, M. U., Wiher, T., Guenther, G. G., Kono, M., Sasaki, A. T., Weisman, L. S., Potma, E. O., Tromberg, B. J., Edwards, R. A., Hanessian, S., & Edinger, A. L.
Affiliations
  • University of California, Irvine (US)
  • Université de Montréal (CA)
  • University of Michigan (US)
  • University of Cincinnati (US)
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
Venue
Journal of Clinical Investigation
Published
2016-09-26
Volume
126
Issue
11
Pages
4088-4102
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2521870368
Cited by
77
References
62
Citations by year
2026: 5 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 12 · 2020: 4 · 2019: 11 · 2018: 14 · 2017: 6 · 2016: 1
FWCI
4.45
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • American Cancer Society (W81XWH-15-1-0010, W81XWH-11-1-0535, RSG-11–111-01-CDD, R21 CA178230, R01 GM089919)
  • William Lawrence and Blanche Hughes Foundation
  • National Institutes of Health (RSG-11-111-01-CDD, W81XWH-11-1-0535, UL1TR001414, W81XWH-15-1-0010, W81XWH, UL1TR000153, TR000153)
  • University of California, Irvine (RSG-11-111-01-CDD, T32 CA009054, R01 GM089919, CA-62203, W81XWH-11-1-0535, UL1 TR000153, R21 CA178230, W81XWH-15-1-0010)
  • National Cancer Institute (R21CA178230, P30CA062203, T32CA009054)
  • National Institute of General Medical Sciences (R01GM050403, R01GM089919)
  • National Institute of Neurological Disorders and Stroke (R01NS064015, R01NS089815)
  • National Institute of Biomedical Imaging and Bioengineering (P41EB015890)
  • National Center for Advancing Translational Sciences
  • Council on Research, Computing, and Libraries, University of California, Irvine
  • Congressionally Directed Medical Research Programs (W81XWH-11-1-0535, R01 GM089919, R21 CA178230, W81XWH-15-1-0010, RSG-11-111-01-CDD)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Keywords
cancer metabolism, nutrient transporters, macropinocytosis, autophagy, lysosome fusion, PIKfyve, PI(3,5)P2, protein phosphatase 2A, oncogenic Ras, tumor heterogeneity, starvation therapy
MeSH terms
Animals, Biological Transport, Active, Drug Screening Assays, Antitumor, Humans, Neoplasm Proteins, Neoplasms, Sphingolipids, Phosphatidylinositol Phosphates, Mice, Knockout, Phosphatidylinositol 3-Kinases, Enzyme Activators, Cell Line, Tumor, Mice, Protein Phosphatase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review